DOCSLIB.ORG

Control Substance List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Control Substance List Drugs DrugID SubstanceName DEANumbScheNarco OtherNames 1 1-(1-Phenylcyclohexyl)pyrrolidine 7458 I N PCPy, PHP, rolicyclidine 2 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine 9663 I Y PEPAP, synthetic heroin 3 1-[1-(2-Thienyl)cyclohexyl]piperidine 7470 I N TCP, tenocyclidine 4 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine 7473 I N TCPy 5 13Beta-ethyl-17beta-hydroxygon-4-en-3-one 4000 III N 6 17Alpha-methyl-3alpha,17beta-dihydroxy-5alpha-androstane 4000 III N 7 17Alpha-methyl-3beta,17beta-dihydroxy-5alpha-androstane 4000 III N 8 17Alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene 4000 III N 9 17Alpha-methyl-4-hydroxynandrolone (17alpha-methyl-4-hyd 4000 III N 10 17Alpha-methyl-delta1-dihydrotestosterone (17beta-hydroxy- 4000 III N 17-Alpha-methyl-1-testosterone 11 19-Nor-4-androstenediol (3beta,17beta-dihydroxyestr-4-ene; 4000 III N 12 19-Nor-4-androstenedione (estr-4-en-3,17-dione) 4000 III N 13 19-Nor-5-androstenediol (3beta,17beta-dihydroxyestr-5-ene; 4000 III N 14 19-Nor-5-androstenedione (estr-5-en-3,17-dione) 4000 III N 15 1-Androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1- 4000 III N 16 1-Androstenedione (5alpha-androst-1-en-3,17-dione) 4000 III N 17 1-Methyl-4-phenyl-4-propionoxypiperidine 9661 I Y MPPP, synthetic heroin 18 1-Phenylcyclohexylamine 7460 II N PCP precursor 19 1-Piperidinocyclohexanecarbonitrile 8603 II N PCC, PCP precursor 20 2,5-Dimethoxy-4-(n)-propylthiophenethylamine 7348 I N 2C-T-7 21 2,5-Dimethoxy-4-ethylamphetamine 7399 I N DOET 22 2,5-Dimethoxyamphetamine 7396 I N DMA, 2,5-DMA 23 3,4,5-Trimethoxyamphetamine 7390 I N TMA 24 3,4-Methylenedioxyamphetamine 7400 I N MDA, Love Drug 25 3,4-Methylenedioxymethamphetamine 7405 I N MDMA, Ecstasy, XTC 26 3,4-Methylenedioxy-N-ethylamphetamine 7404 I N N-ethyl MDA, MDE, MDEA 27 3Alpha,17beta-dihydroxy-5alpha-androstane 4000 III N 28 3Beta,17beta-dihydroxy-5alpha-androstane 4000 III N 29 3-Methylfentanyl 9813 I Y China White, fentanyl 30 3-Methylthiofentanyl 9833 I Y Chine White, fentanyl 31 4-Androstenediol (3beta,17beta-dihydroxy-androst-4-ene) 4000 III N 4-AD 32 4-Androstenedione (androst-4-en-3,17-dione) 4000 III N 33 4-Bromo-2,5-dimethoxyamphetamine 7391 I N DOB, 4-bromo-DMA 34 4-Bromo-2,5-dimethoxyphenethylamine 7392 I N 2C-B, Nexus, has been sold as Ecstasy, i.e. MDMA 35 4-Dihydrotestosterone (17beta-hydroxyandrostan-3-one) 4000 III N Anabolex, Andractim, Pesomax, Stanolone 36 4-Hydroxy-19-nortestosterone (4,17beta-dihydroxyestr-4-en-3 4000 III N Page 1 Drugs 37 4-Hydroxytestosterone (4,17beta-dihydroxyandrost-4-en-3-on 4000 III N 38 4-Methoxyamphetamine 7411 I N PMA 39 4-Methyl-2,5-dimethoxyamphetamine 7395 I N DOM, STP 40 4-Methylaminorex (cis isomer) 1590 I N U4Euh, McN-422 41 5-Androstenediol (3beta,17beta-dihydroxy-androst-5-ene) 4000 III N 42 5-Androstenedione (androst-5-en-3,17-dione) 4000 III N 43 5-Methoxy-3,4-methylenedioxyamphetamine 7401 I N MMDA 44 5-Methoxy-N,N-diisopropyltryptamine 7439 I N 5-MeO-DIPT 45 Acetorphine 9319 I Y 46 Acetyl-alpha-methylfentanyl 9815 I Y 47 Acetyldihydrocodeine 9051 I Y Acetylcodone 48 Acetylmethadol 9601 I Y Methadyl acetate 49 Alfentanil 9737 II Y Alfenta 50 Allylprodine 9602 I Y 51 Alphacetylmethadol except levo-alphacetylmethadol 9603 I Y 52 Alpha-ethyltryptamine 7249 I N ET, Trip 53 Alphameprodine 9604 I Y 54 Alphamethadol 9605 I Y 55 Alpha-methylfentanyl 9814 I Y China White, fentanyl 56 Alpha-methylthiofentanyl 9832 I Y China White, fentanyl 57 Alpha-methyltryptamine 7432 I N AMT 58 Alphaprodine 9010 II Y Nisentil 59 Alprazolam 2882 IV N Xanax 60 Aminorex 1585 I N has been sold as methamphetamine 61 Amobarbital 2125 II N Amytal, Tuinal 62 Amobarbital & noncontrolled active ingred. 2126 III N 63 Amobarbital suppository dosage form 2126 III N 64 Amphetamine 1100 II N Dexedrine, Adderall, Obetrol 65 Anabolic steroids 4000 III N "Body Building" drugs 66 Androstanedione (5alpha-androstan-3,17-dione) 4000 III N 67 Anileridine 9020 II Y Leritine 68 Aprobarbital 2100 III N Alurate 69 Barbital 2145 IV N Veronal, Plexonal, barbitone 70 Barbituric acid derivative 2100 III N Barbiturates not specifically listed 71 Benzethidine 9606 I Y 72 Benzoylecgonine 9180 II Y Cocaine metabolite 73 Benzphetamine 1228 III N Didrex, Inapetyl Page 2 Drugs 74 Benzylmorphine 9052 I Y 75 Betacetylmethadol 9607 I Y 76 Beta-hydroxy-3-methylfentanyl 9831 I Y China White, fentanyl 77 Beta-hydroxyfentanyl 9830 I Y China White, fentanyl 78 Betameprodine 9608 I Y 79 Betamethadol 9609 I Y 80 Betaprodine 9611 I Y 81 Bezitramide 9800 II Y Burgodin 82 Bolasterone (7alpha,17alpha-dimethyl-17beta-hydroxyandros 4000 III N 83 Boldenone (17beta-hydroxyandrost-1,4-diene-3-one) 4000 III N Equipoise, Parenabol, Vebonol, dehydrotestosterone 84 Bromazepam 2748 IV N Lexotan, Lexatin, Lexotanil 85 Bufotenine 7433 I N Mappine, N,N-dimethylserotonin 86 Buprenorphine 9064 III Y Buprenex, Temgesic, Subutex, Suboxone 87 Butabarbital (secbutabarbital) 2100 III N Butisol, Butibel 88 Butalbital 2100 III N Fiorinal, Butalbital with aspirin 89 Butobarbital (butethal) 2100 III N Soneryl (UK) 90 Butorphanol 9720 IV N Stadol, Stadol NS, Torbugesic, Torbutrol 91 Calusterone (7beta,17alpha-dimethyl-17beta-hydroxyandrost 4000 III N Methosarb 92 Camazepam 2749 IV N Albego, Limpidon, Paxor 93 Carfentanil 9743 II Y Wildnil 94 Carisoprodol IV N Soma 95 Cathine 1230 IV N Constituent of "Khat" plant 96 Cathinone 1235 I N Constituent of "Khat" plant 97 Chloral betaine 2460 IV N Beta Chlor 98 Chloral hydrate 2465 IV N Noctec 99 Chlordiazepoxide 2744 IV N Librium, Libritabs, Limbitrol, SK-Lygen 100 Chlorhexadol 2510 III N Mechloral, Mecoral, Medodorm, Chloralodol 101 Chlorphentermine 1645 III N Pre-Sate, Lucofen, Apsedon, Desopimon 102 Clobazam 2751 IV N Urbadan, Urbanyl 103 Clonazepam 2737 IV N Klonopin, Clonopin 104 Clonitazene 9612 I Y 105 Clorazepate 2768 IV N Tranxene 106 Clortermine 1647 III N Voranil 107 Clostebol (4-chloro-17beta-hydroxyandrost-4-en-3-one) 4000 III N Alfa-Trofodermin, Clostene, 4-chlorotestosterone 108 Clotiazepam 2752 IV N Trecalmo, Rize, Clozan, Veratran 109 Cloxazolam 2753 IV N Akton, Lubalix, Olcadil, Sepazon 110 Coca Leaves 9040 II Y Page 3 Drugs 111 Cocaine 9041 II Y Methyl benzoylecgonine, Crack 112 Codeine 9050 II Y Morphine methyl ester, methyl morphine 113 Codeine & isoquinoline alkaloid 90 mg/du 9803 III Y Codeine with papaverine or noscapine 114 Codeine combination product 90 mg/du 9804 III Y Empirin,Fiorinal,Tylenol,ASA or APAP w/codeine 115 Codeine methylbromide 9070 I Y 116 Codeine-N-oxide 9053 I Y 117 Cyprenorphine 9054 I Y 118 Dehydrochloromethyltestosterone (4-chloro-17beta-hydroxy- 4000 III N Oral-Turinabol 119 Delorazepam 2754 IV N 120 Delta1-dihydrotestosterone (17beta-hydroxy-5alpha-androst- 4000 III N 1-Testosterone 121 Desomorphine 9055 I Y 122 Dexfenfluramine 1670 IV N Redux 123 Dextromoramide 9613 I Y Palfium, Jetrium, Narcolo 124 Dextropropoxyphene dosage forms 9278 IV Y Darvon, propoxyphene, Darvocet, Propacet 125 Dextropropoxyphene, bulk (non-dosage forms) 9273 II Y Propoxyphene 126 Diampromide 9615 I Y 127 Diazepam 2765 IV N Valium, Diastat 128 Dichloralphenazone 2467 IV N Midrin, dichloralantipyrine 129 Diethylpropion 1610 IV N Tenuate, Tepanil 130 Diethylthiambutene 9616 I Y 131 Diethyltryptamine 7434 I N DET 132 Difenoxin 9168 I Y Lyspafen 133 Difenoxin 1 mg/25 ug AtSO4/du 9167 IV Y Motofen 134 Dihydrocodeine 9120 II Y Didrate, Parzone 135 Dihydrocodeine combination product 90 mg/du 9807 III Y Synalgos-DC, Compal 136 Dihydroetorphine 9334 II Y DHE 137 Dihydromorphine 9145 I Y 138 Dimenoxadol 9617 I Y 139 Dimepheptanol 9618 I Y 140 Dimethylthiambutene 9619 I Y 141 Dimethyltryptamine 7435 I N DMT 142 Dioxaphetyl butyrate 9621 I Y 143 Diphenoxylate 9170 II Y 144 Diphenoxylate and Atropine V N Lomotil, Lonox 145 Dipipanone 9622 I Y Dipipan, phenylpiperone HCl, Diconal, Wellconal 146 Diprenorphine 9058 II Y M50-50 147 Dronabinol in sesame oil in soft gelatin capsule 7369 III N Marinol, synthetic THC in sesame oil/soft gelatin Page 4 Drugs 148 Drostanolone (17beta-hydroxy-2alpha-methyl-5alpha-androst 4000 III N Drolban, Masterid, Permastril 149 Drotebanol 9335 I Y Metebanyl, oxymethebanol 150 Ecgonine 9180 II Y Cocaine precursor, in Coca leaves 151 Estazolam 2756 IV N ProSom, Domnamid, Eurodin, Nuctalon 152 Ethchlorvynol 2540 IV N Placidyl 153 Ethinamate 2545 IV N Valmid, Valamin 154 Ethyl loflazepate 2758 IV N 155 Ethylestrenol (17alpha-ethyl-17beta-hydroxyestr-4-ene) 4000 III N Maxibolin, Orabolin, Durabolin-O, Duraboral 156 Ethylmethylthiambutene 9623 I Y 157 Ethylmorphine 9190 II Y Dionin 158 Ethylmorphine combination product 15 mg/du 9808 III Y 159 Etonitazene 9624 I Y 160 Etorphine (except HCl) 9056 I Y 161 Etorphine HCl 9059 II Y M 99 162 Etoxeridine 9625 I Y 163 Fencamfamin 1760 IV N Reactivan 164 Fenethylline 1503 I N Captagon,amfetyline,ethyltheophylline amphetamine 165 Fenfluramine 1670 IV N Pondimin, Ponderal 166 Fenproporex 1575 IV N Gacilin, Solvolip 167 Fentanyl 9801 II Y Duragesic, Oralet, Actiq, Sublimaze, Innovar 168 Fludiazepam 2759 IV N 169 Flunitrazepam 2763 IV N Rohypnol, Narcozep, Darkene, Roipnol 170 Fluoxymesterone (9-fluoro-17alpha-methyl-11beta,17beta-dih 4000 III N Anadroid-F, Halotestin, Ora-Testryl 171 Flurazepam 2767 IV N Dalmane 172 Formebolone (2-formyl-17alpha-methyl-11alpha,17beta-dihyd 4000 III N Esiclene, Hubernol 173 Furazabol (17alpha-methyl-17beta-hydroxyandrostano[2,3-c] 4000 III N Frazalon, Miotolon, Qu Zhi Shu 174 Furethidine 9626 I Y 175 Gamma Hydroxybutyric Acid 2010 I N GHB, gamma hydroxybutyrate, sodium oxybate 176 Gamma Hydroxybutyric Acid preparations 2012 III N Zyrem 177 Glutethimide
Load more

Recommended publications
  • Ionization Energies of Benzodiazepines Salvatore Millefiori, Andrea Alparone
    Electronic properties of neuroleptics: ionization energies of benzodiazepines Salvatore Millefiori, Andrea Alparone To cite this version: Salvatore Millefiori, Andrea Alparone. Electronic properties of neuroleptics: ionization energies of benzodiazepines. Journal of Molecular Modeling, Springer Verlag (Germany), 2010, 17 (2), pp.281- 287. 10.1007/s00894-010-0723-7. hal-00590996 HAL Id: hal-00590996 https://hal.archives-ouvertes.fr/hal-00590996 Submitted on 6 May 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Editorial Manager(tm) for Journal of Molecular Modeling Manuscript Draft Manuscript Number: JMMO1191R1 Title: Electronic properties of neuroleptics: ionization energies of benzodiazepines Article Type: Original paper Keywords: Benzodiazepines; vertical ionization energies; vertical electron affinities; DFT calculations; electron propagator theory calculations. Corresponding Author: Prof. Salvatore Millefiori, Corresponding Author's Institution: First Author: Salvatore Millefiori Order of Authors: Salvatore Millefiori; Andrea Alparone Abstract: Abstract. Vertical ionization energies (VIEs) of medazepam and nordazepam and of their molecular subunits have been calculated with the electron propagator method in the P3/CEP-31G* approximation. Vertical electron affinities (VEAs) have been obtained with a ΔSCF procedure at the DFT-B3LYP/6-31+G* level of theory. Excellent correlations have been achieved between IEcalc and IEexp allowing reliable assignment of the ionization processes.
    [Show full text]
  • Noscapine Suppresses Angiotensin Converting Enzyme Inhibitors-Induced Cough
    Blackwell Science, LtdOxford, UKNEPNephrology1320-53582005 Asian Pacific Society of NephrologyAugust 2005104348350Original ArticleNoscapine suppresses ACEI-induced coughA Mooraki et al. NEPHROLOGY 2005; 10, 348–350 doi:10.1111/j.1440-1797.2005.00429.x Original Article Noscapine suppresses angiotensin converting enzyme inhibitors-induced cough AHMAD MOORAKI,1 ARIA JENABI,1 MOSADEGH JABBARI,1 MOHAMMAD I ZOLFAGHARI,2 SAHAR Z JAVANMARDI,2 MASOUD MAHMOUDIAN3 and BAHAR BASTANI4 1Division of Nephrology, Rasool Akram Medical Center and 3Razi Institute for Drug Research, Iran University of Medical Sciences and 2Department of Pharmacology, School of Pharmacy, Azad University, Iran and 4Division of Nephrology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA SUMMARY: Background: Dry cough is a common side-effect of the angiotensin converting enzyme inhibitors (ACEI) and is a major limiting factor of their use. It has been suggested that ACEI cause this side-effect by potentiation of the bradykinin effect. Previous work in our laboratory has shown that noscapine, an antitussive drug, inhibits the effect of bradykinin. Methods: To investigate the effect of noscapine on ACEI-induced cough, 611 hypertensive patients who were being treated with ACEI were evaluated for the incidence of persistent dry cough. Results: A cough had developed in 65 (10.6%) patients, two (3.1%) of whom also had severe respiratory dis- tress that required hospitalisation and immediate discontinuation of the ACEI. Forty-two (64.6%) patients had developed a mild cough and 21 (32.3%) patients had developed a moderate to severe cough. The patients with moderate to severe cough received 15 mg of noscapine, orally three times daily, while they continued ACEI.
    [Show full text]
  • Anabolic-Androgenic Steroids in Horses: Natural Presence and Underlying Biomechanisms
    ANABOLIC-ANDROGENIC STEROIDS IN HORSES: NATURAL PRESENCE AND UNDERLYING BIOMECHANISMS Anneleen Decloedt Dissertation submitted in the fulfilment of the requirements for the degree of Doctor of philosophy (PhD) in Veterinary Sciences, Faculty of Veterinary Medicine, Ghent University PROMOTER Prof. dr. ir. Lynn Vanhaecke Ghent University, Faculty of Veterinary Medicine Department of Veterinary Public Health and Food Safety Laboratory of Chemical Analysis MEMBERS OF THE READING COMMITTEE Prof. dr. James Scarth HFL Sport Science, Cambridgeshire, United-Kingdom Prof. dr. Peter Van Eenoo Ghent University, DoCoLab, Zwijnaarde, Belgium Prof. dr. Ann Van Soom Ghent University, Faculty of Veterinary Medicine, Merelbeke, Belgium MEMBERS OF THE EXAMINATION COMMITTEE Dr. Ludovic Bailly-Chouriberry Laboratoires des Courses Hippiques, Verrières-le-Buisson, France Dr. Leen Van Ginkel Wageningen University, RIKILT, Wageningen, The Netherlands Prof. dr. Myriam Hesta Ghent University, Faculty of Veterinary Medicine, Merelbeke, Belgium This work was funded by the Fédération Nationale des Courses Françaises (via the Laboratoire des Courses Hippiques) and executed at the Laboratory of Chemical Analysis (Faculty of Veterinary Medicine, Ghent University, Merelbeke). The author and the promoter give the authorisation to consult and to copy parts of this work for personal use only. Every other use is subject to the copyright laws. Permission to reproduce any material contained in this work should be obtained from the author. “The universe is full of magic, Just patiently waiting for our wits to grow sharper” TABLE OF CONTENTS TABLE OF CONTENTS Chapter I – General Introduction 1 1. Steroids 3 1.1 Chemical structure 1.2 (Steroid) hormones and their role in the endocrine system 1.3 Biosynthesis of steroid hormones 1.4 Anabolic-androgenic steroids (AAS) 1.5 Synthesis and absorption of the steroid precursor cholesterol 2.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • MICROCOMP Output File
    108TH CONGRESS 2D SESSION S. 2195 AN ACT To amend the Controlled Substances Act to clarify the defini- tion of anabolic steroids and to provide for research and education activities relating to steroids and steroid precursors. 1 Be it enacted by the Senate and House of Representa- 2 tives of the United States of America in Congress assembled, 3 SECTION 1. SHORT TITLE. 4 This Act may be cited as the ‘‘Anabolic Steroid Con- 5 trol Act of 2004’’. 2 1 SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES 2 ACT. 3 (a) DEFINITIONS.—Section 102 of the Controlled 4 Substances Act (21 U.S.C. 802) is amended— 5 (1) in paragraph (41)— 6 (A) by realigning the margin so as to align 7 with paragraph (40); and 8 (B) by striking subparagraph (A) and in- 9 serting the following: 10 ‘‘(A) The term ‘anabolic steroid’ means any drug or 11 hormonal substance, chemically and pharmacologically re- 12 lated to testosterone (other than estrogens, progestins, 13 corticosteroids, and dehydroepiandrosterone), and 14 includes— 15 ‘‘(i) androstanediol— 16 ‘‘(I) 3β,17β-dihydroxy-5α-androstane; and 17 ‘‘(II) 3α,17β-dihydroxy-5α-androstane; 18 ‘‘(ii) androstanedione (5α-androstan-3,17- 19 dione); 20 ‘‘(iii) androstenediol— 21 ‘‘(I) 1-androstenediol (3β,17β-dihydroxy- 22 5α-androst-1-ene); 23 ‘‘(II) 1-androstenediol (3α,17β-dihydroxy- 24 5α-androst-1-ene); 25 ‘‘(III) 4-androstenediol (3β,17β-dihydroxy- 26 androst-4-ene); and †S 2195 ES 3 1 ‘‘(IV) 5-androstenediol (3β,17β-dihydroxy- 2 androst-5-ene); 3 ‘‘(iv) androstenedione— 4 ‘‘(I) 1-androstenedione ([5α]-androst-1-en- 5 3,17-dione);
    [Show full text]
  • UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST
    UFC PROHIBITED LIST Effective June 1, 2021 THE UFC PROHIBITED LIST UFC PROHIBITED LIST Effective June 1, 2021 PART 1. Except as provided otherwise in PART 2 below, the UFC Prohibited List shall incorporate the most current Prohibited List published by WADA, as well as any WADA Technical Documents establishing decision limits or reporting levels, and, unless otherwise modified by the UFC Prohibited List or the UFC Anti-Doping Policy, Prohibited Substances, Prohibited Methods, Specified or Non-Specified Substances and Specified or Non-Specified Methods shall be as identified as such on the WADA Prohibited List or WADA Technical Documents. PART 2. Notwithstanding the WADA Prohibited List and any otherwise applicable WADA Technical Documents, the following modifications shall be in full force and effect: 1. Decision Concentration Levels. Adverse Analytical Findings reported at a concentration below the following Decision Concentration Levels shall be managed by USADA as Atypical Findings. • Cannabinoids: natural or synthetic delta-9-tetrahydrocannabinol (THC) or Cannabimimetics (e.g., “Spice,” JWH-018, JWH-073, HU-210): any level • Clomiphene: 0.1 ng/mL1 • Dehydrochloromethyltestosterone (DHCMT) long-term metabolite (M3): 0.1 ng/mL • Selective Androgen Receptor Modulators (SARMs): 0.1 ng/mL2 • GW-1516 (GW-501516) metabolites: 0.1 ng/mL • Epitrenbolone (Trenbolone metabolite): 0.2 ng/mL 2. SARMs/GW-1516: Adverse Analytical Findings reported at a concentration at or above the applicable Decision Concentration Level but under 1 ng/mL shall be managed by USADA as Specified Substances. 3. Higenamine: Higenamine shall be a Prohibited Substance under the UFC Anti-Doping Policy only In-Competition (and not Out-of- Competition).
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • Backing Material Packaging Liner
    US009314527B2 (12) United States Patent (10) Patent No.: US 9,314,527 B2 Cottrell et al. (45) Date of Patent: *Apr. 19, 2016 (54) TRANSDERMAL DELIVERY PATCH 9/7061 (2013.01); A61K 9/7084 (2013.01); (71) Applicant: Phosphagenics Limited, Clayton, A61 K3I/355 (2013.01); A61K47/24 Victoria (AU) SE7 8E.O. (72) Inventors: Jeremy Cottrell, Caulfield South (AU); ( .01): ( .01): (2013.01) Giacinto Gaetano, South Melbourne (AU); Mahmoud El-Tamimy, Meadow (58) Field of Classification Search Heights (AU); Nicholas Kennedy, None Boronia (AU); Paul David Gavin, See application file for complete search history. Chadstone (AU) (56) References Cited (73) Assignee: Phosphagenics Limited, Victoria (AU) (*) Notice: Subject to any disclaimer, the term of this U.S. PATENT DOCUMENTS patent is extended or adjusted under 35 2,407,823. A 9, 1946 Fieser U.S.C. 154(b) by 0 days. 2.457,932 A 1/1949 Solmssen et al. This patent is Subject to a terminal dis- (Continued) claimer. (21) Appl. No.: 14/550,514 FOREIGN PATENT DOCUMENTS ppl. No.: 9 (22) Filed: Nov. 21, 2014 A 3.3 5.83 (65) Prior Publication Data (Continued) Related U.S. Application Data Gianello et al. Subchronic Oral Toxicity Study of Mixed Tocopheryl (63) Continuation of application No. 14/086,738, filed on Phosphates in Rates, International Journal of Toxicology, 26:475 Nov. 21, 2013, now abandoned, which is a 490; 2007.* continuation of application No. 13/501,500, filed as (Continued) application No. PCT/AU2011/000358 on Mar. 30, 2011, now Pat. No. 8,652,511. Primary Examiner — Robert A Wax (60) Provisional application No.
    [Show full text]
  • CONTROLLED SUBSTANCE, DRUG, DEVICE and COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun
    CONTROLLED SUBSTANCE, DRUG, DEVICE AND COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun. 23, 2011, P.L. 36, No. 7 Cl. 35 Session of 2011 No. 2011-7 SB 1006 AN ACT Amending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for Schedule I controlled substances. The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows: Section 1. Section 4(1) of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, amended November 24, 1999 (P.L.894, No.55), is amended to read: Section 4. Schedules of Controlled Substances.--The following schedules include the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. (1) Schedule I--In determining that a substance comes within this schedule, the secretary shall find: a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. The following controlled substances are included in this schedule: (i) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation: 1.
    [Show full text]
  • Federal Controlled Substances Checklist
    Federal Controlled Substances Checklist Introduction By Norton Tooby & Joseph Justin Rollin We have reprinted here an alphabetical list of all controlled substances forbidden under federal drug laws, taken from the official website of the U.S. Department of Justice, Drug Enforcement Administration, Office of Diversion Control, at http://www.justice.gov/dea/pubs/scheduling.html. No copyright is asserted to this information. This list changes frequently. The official list is contained at 21 CFR § 1308, as supplemented by final rules published in the Federal Register. The attached checklist of controlled substances has been compiled into one list, and placed in alphabetical order, for ease of reference. If a controlled substance is listed in the federal drug schedules, it triggers deportation, INA § 237(a)(2)(B)(i), 8 U.S.C. § 1227(a)(2)(B)(i), and inadmissibility. INA § 212(a)(2)(A)(i)(II), 8 U.S.C. § 1182(a)(2)(A)(i)II). In addition, there is an aggravated felony defined as illicit trafficking in a controlled substance. INA § 101(a)(43)(B), 8 U.S.C. § 1101(a)(43)(B). The same controlled substance lists apply to this ground of deportation as well. If a drug is not listed on the federal controlled substances schedules, it does not trigger removal under these grounds. In addition, because the government has the burden of proof in deportation removal proceedings by clear and convincing evidence, if the record of conviction is ambiguous as to whether the specific substance involved in the particular case was listed on the federal schedules, the government cannot obtain a deportation removal order on this ground.
    [Show full text]
  • Proposed Regulation of the State Board of Pharmacy
    PROPOSED REGULATION OF THE STATE BOARD OF PHARMACY LCB File No. R133-14 Workshop July 24, 2014 NAC 453.540 Schedule IV. (NRS 453.146, 639.070) 1. Schedule IV consists of the drugs and other substances listed in this section, by whatever official, common, usual, chemical or trade name designated. 2. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs, including, without limitation, their salts, calculated as the free anhydrous base of alkaloid, is hereby enumerated on schedule IV, in quantities: (a) Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit; or (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxy- butane). 3. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including, without limitation, their salts, isomers and salts of isomers, is hereby enumerated on schedule IV, whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation: Alprazolam; Barbital; Bromazepam; Butorphanol; Camazepam; Carisoprodol; Chloral betaine; Chloral hydrate; Chlordiazepoxide; Clobazam; Clonazepam; Clorazepate; Clotiazepam; Cloxazolam; Delorazepam; Diazepam; Dichloralphenazone; Estazolam; Ethchlorvynol; Ethyl loflazepate; Fludiazepam; Flunitrazepam; --1-- Agency Draft of Proposed Regulation R133-14 Flurazepam; Halazepam; Haloxazolam; Ketazolam; Loprazolam; Lorazepam; Lormetazepam; Mebutamate; Medazepam; Meprobamate; Methohexital; Methylphenobarbital (mephobarbital); Midazolam; Nimetazepam; Nitrazepam; Nordiazepam; Oxazepam; Oxazolam; Paraldehyde; Petrichloral; Phenobarbital; Pinazepam; Prazepam; Quazepam; Tramadol (2-((dimethylamino)methyl)-1-(3-methoxyphenyl)cyclohexanol) Temazepam; Tetrazepam; Triazolam; Zaleplon; Zolpidem; or Zopiclone.
    [Show full text]
  • Benzodiazepine Group ELISA Kit
    Benzodiazepine Group ELISA Kit Benzodiazepine Background Since their introduction in the 1960s, benzodiazepines have been widely prescribed for the treatment of anxiety, insomnia, muscle spasms, alcohol withdrawal, and seizure-prevention as they are depressants of the central nervous system. Despite the fact that they are highly effective for their intended use, benzodiazepines are prescribed with caution as they can be highly addictive. In fact, researchers at NIDA (National Institute on Drug Abuse) have shown that addiction for benzodiazepines is similar to that of opioids, cannabinoids, and GHB. Common street names of benzodiazepines include “Benzos” and “Downers”. The five most encountered benzodiazepines on the illicit market are alprazolam (Xanax), lorazepam (Ativan), clonazepam (Klonopin), diazepam (Valium), and temazepam (Restori). The method of abuse is typically oral or snorted in crushed form. The DEA notes a particularly high rate of abuse among heroin and cocaine abusers. Designer benzodiazepines are currently offered in online shops selling “research chemicals”, providing drug abusers an alternative to prescription-only benzodiazepines. Data defining pharmacokinetic parameters, drug metabolisms, and detectability in biological fluids is limited. This lack of information presents a challenge to forensic laboratories. Changes in national narcotics laws in many countries led to the control of (phenazepam and etizolam), which were marketed by pharmaceutical companies in some countries. With the control of phenazepam and etizolam, clandestine laboratories have begun researching and manufacturing alternative benzodiazepines as legal substitutes. Delorazepam, diclazepam, pyrazolam, and flubromazepam have emerged as compounds in this class of drugs. References Drug Enforcement Administration, Office of Diversion Control. “Benzodiazepines.” http://www.deadiversion.usdoj.gov/drugs_concern/benzo_1.
    [Show full text]